Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,831 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study.
Nishimura T, Ichihara E, Yokoyama T, Inoue K, Tamura T, Sato K, Oda N, Kano H, Kishino D, Kawai H, Inoue M, Ochi N, Fujimoto N, Ichikawa H, Ando C, Hotta K, Maeda Y, Kiura K. Nishimura T, et al. Among authors: yokoyama t. Cancers (Basel). 2022 Dec 14;14(24):6184. doi: 10.3390/cancers14246184. Cancers (Basel). 2022. PMID: 36551668 Free PMC article.
Desire for information and involvement in treatment decisions: lung cancer patients' preferences and their physicians' perceptions: results from Okayama Lung Cancer Study Group Trial 0705.
Hotta K, Kiura K, Takigawa N, Yoshioka H, Hayashi H, Fukuyama H, Nishiyama A, Yokoyama T, Kuyama S, Umemura S, Kato Y, Nogami N, Segawa Y, Yasugi M, Tabata M, Tanimoto M. Hotta K, et al. Among authors: yokoyama t. J Thorac Oncol. 2010 Oct;5(10):1668-72. doi: 10.1097/JTO.0b013e3181f1c8cb. J Thorac Oncol. 2010. PMID: 20871267 Free article.
Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403.
Oda N, Ichihara E, Hotta K, Ninomiya K, Ninomiya T, Kubo T, Minami D, Murakami T, Yokoyama T, Harada D, Kuyama S, Ichikawa H, Inoue K, Kishino D, Inoue M, Takigawa N, Shibayama T, Harita S, Tanimoto M, Kiura K. Oda N, et al. Among authors: yokoyama t. Clin Lung Cancer. 2017 Mar;18(2):241-244. doi: 10.1016/j.cllc.2016.07.003. Epub 2016 Jul 9. Clin Lung Cancer. 2017. PMID: 27506489 Clinical Trial.
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.
Oda N, Hotta K, Ninomiya K, Minami D, Ichihara E, Murakami T, Yokoyama T, Ichikawa H, Chikamori K, Takigawa N, Ochi N, Harita S, Maeda Y, Kiura K. Oda N, et al. Among authors: yokoyama t. Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1. Cancer Chemother Pharmacol. 2018. PMID: 30276451 Clinical Trial.
Phase 2 Study of Afatinib Alone or Combined With Bevacizumab in Chemonaive Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: AfaBev-CS Study Protocol.
Ninomiya T, Ishikawa N, Inoue K, Kubo T, Yasugi M, Shibayama T, Maeda T, Fujitaka K, Kodani M, Yokoyama T, Kuyama S, Ochi N, Ueda Y, Miyoshi S, Kozuki T, Amano Y, Kubota T, Sugimoto K, Bessho A, Ishii T, Watanabe K, Oze I, Hotta K, Kiura K. Ninomiya T, et al. Among authors: yokoyama t. Clin Lung Cancer. 2019 Mar;20(2):134-138. doi: 10.1016/j.cllc.2018.10.008. Epub 2018 Nov 1. Clin Lung Cancer. 2019. PMID: 30514667
A phase I/II trial of weekly nab-paclitaxel for pretreated non-small-cell lung cancer patients without epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangement.
Harada D, Kozuki T, Nogami N, Bessho A, Hosokawa S, Fukamatsu N, Hotta K, Ohashi K, Kubo T, Yoshioka H, Yokoyama T, Sone N, Kuyama S, Kudo K, Yasugi M, Takigawa N, Oze I, Kiura K. Harada D, et al. Among authors: yokoyama t. Asia Pac J Clin Oncol. 2019 Aug;15(4):250-256. doi: 10.1111/ajco.13147. Epub 2019 Apr 1. Asia Pac J Clin Oncol. 2019. PMID: 30938103 Free PMC article. Clinical Trial.
Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D, Isozaki H, Kozuki T, Yokoyama T, Yoshioka H, Bessho A, Hosokawa S, Takata I, Takigawa N, Hotta K, Kiura K; Okayama Lung Cancer Study Group. Harada D, et al. Among authors: yokoyama t. Thorac Cancer. 2021 Mar;12(5):643-649. doi: 10.1111/1759-7714.13825. Epub 2021 Jan 20. Thorac Cancer. 2021. PMID: 33470536 Free PMC article. Clinical Trial.
A randomized trial of sodium alginate prevention of esophagitis in LA-NSCLC receiving chemoradiotherapy: OLCSG1401.
Ninomiya K, Yokoyama T, Hotta K, Oze I, Katsui K, Hata T, Yoshioka H, Bessho A, Hosokawa S, Kuyama S, Kudo K, Kozuki T, Harada D, Yasugi M, Murakami T, Nakanishi M, Takigawa N, Maeda Y, Kiura K; Okayama Lung Cancer Study Group. Ninomiya K, et al. Among authors: yokoyama t. Support Care Cancer. 2021 Sep;29(9):5237-5244. doi: 10.1007/s00520-021-06092-1. Epub 2021 Mar 1. Support Care Cancer. 2021. PMID: 33649919 Clinical Trial.
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study).
Tanzawa S, Ushijima S, Shibata K, Shibayama T, Bessho A, Kaira K, Misumi T, Shiraishi K, Matsutani N, Tanaka H, Inaba M, Haruyama T, Nakamura J, Kishikawa T, Nakashima M, Iwasa K, Fujiwara K, Kohyama T, Kuyama S, Miyazawa N, Nakamura T, Miyawaki H, Ishida H, Oda N, Ishikawa N, Morinaga R, Kusaka K, Fujimoto N, Yokoyama T, Gemba K, Tsuda T, Nakagawa H, Ono H, Shimizu T, Nakamura M, Kusumoto S, Hayashi R, Shirasaki H, Ochi N, Aoe K, Kanaji N, Kashiwabara K, Inoue H, Seki N. Tanzawa S, et al. Among authors: yokoyama t. Ther Adv Med Oncol. 2021 Feb 27;13:1758835921998588. doi: 10.1177/1758835921998588. eCollection 2021. Ther Adv Med Oncol. 2021. PMID: 33717228 Free PMC article.
3,831 results